乌鸦传媒

Oncology/Hematology

<乌鸦传媒 class='mpt-top_cat_title_description'>News, opinions and meeting coverage in oncology/hematology.

<乌鸦传媒>Part 2: Oncologists Weigh In on PBS Cancer Documentary

Six specialists share their impressions of Ken Burns' cancer opus.

<乌鸦传媒>Brain Cancer: Did '60 Minutes' Report Raise False Hope?

Glioblastoma virotherapy touted on CBS program is promising but preliminary.

<乌鸦传媒>AAD: Frog Enzyme Clears Genital Warts

Summaries of late-breaking research from the dermatology meeting.

<乌鸦传媒>Frankie the Dog Fetches - and Finds Thyroid Cancer?

Canine trained in cancer scent detection gives few false positives in early test.

<乌鸦传媒>Seeds Top EBRT as Boost Tx in Prostate Cancer

And other advances in prostate cancer care from the Genitourinary Cancers Symposium.

<乌鸦传媒>HDAC Inhibitor OK'd for Multiple Myeloma

Panobinostat targets histone deacetylases; first of its kind to win approval in myeloma.

<乌鸦传媒>Predicting Death in Advanced Cancer

Study offers clues to guide clinicians, families about end of life.

<乌鸦传媒>CRC Regimens Give Survival Bump in Second Line

Ramucirumab trial meets primary endpoint; famitinib offers respectable disease control rate.

<乌鸦传媒>More Drugs, Better Survival in Metastatic Colon Cancer

Addition of oxaliplatin to FOLFIRI and bevacizumab doubled 5-year survival.

<乌鸦传媒>Scoring System for Lung Cancer Screening Debuts

Radiologists to get tools for grading suspicious lesions.

<乌鸦传媒>Mammograms: Less Pain, Risk-Based Screens?

Breast cancer screening after 40, a more comfortable mammogram.

<乌鸦传媒>Clinical Focus In Renal Cell Carcinoma: Clues from Gene Studies

Mutations in four genes appear to play a key role in the origin of renal cell carcinoma.

<乌鸦传媒>No Need for Cancer Watch in Cirrhotic Wilson's Disease

Hepatocellular carcinoma is too infrequent to merit regular surveillance.

<乌鸦传媒>Evolution: Breast Reconstruction After Mastectomy

Techniques have changed and improved.

<乌鸦传媒>Do Statins Up a Woman's Risk for Thyroid Cancer?

Estrogen may neutralize the cancer-protective effects of cholesterol-lowering drugs.

<乌鸦传媒>That's Not Chronic Lyme, It's Cancer

Three case reports demonstrate the risks of "assuming that patients have chronic Lyme disease."

<乌鸦传媒>'Yes' to Routine Colonoscopies in IBD

Screening lowered colorectal cancer incidence and colon cancer mortality.

<乌鸦传媒>Case Study: Fecal Transplant Clears K. Pneumoniae

Treatment of teenage girl suggests another use for fecal microbiota transplant.

<乌鸦传媒>BCS: 'Jolie Effect' Drives Genetic Test Referrals

SAN FRANCISCO -- Referrals for genetic testing almost doubled in the first 6 months after actress Angelina Jolie said she would undergo bilateral mastectomy after testing positive for BRCA1 mutation.

<乌鸦传媒>New Melanomas Likely to Recur at Same Rate

CHICAGO -- A diagnosis of in situ or invasive melanoma conferred a similar long-term risk of invasive melanoma recurrence, a 40-year retrospective review showed.

<乌鸦传媒>Are Your Patients Using Fake Names?

A case study in the American Journal of Medicine poses a vexing question many healthcare professionals have faced: What should you do when your patients use fraudulent names?

<乌鸦传媒>Morning Break: The B.O. Talk, No Love for Niacin

Health news and commentary from around the Web, gathered by the 乌鸦传媒 staff.

<乌鸦传媒>Friday Feedback: Zero-Tolerance Employment Smoking Bans?

Should hospitals, schools, and companies refuse to hire smokers for teachers and healthcare providers?

<乌鸦传媒>FDA Panel Puts Brakes on Anti-PARP Drug

WASHINGTON -- Approval of a PARP inhibitor for patients with advanced ovarian cancer should await results of an ongoing clinical trial that has the potential to answer questions about the drug's safety and efficacy, according to an FDA advisory committee that voted against immediate approval.

<乌鸦传媒>AMA Clamps Down on MOC, But Punts on Gun Regs

CHICAGO -- The AMA鈥檚 House of Delegates drew the line on this year's hot button topic -- maintenance of certification (MOC), saying it should not be mandatory, nor should it be a condition of licensure.

<乌鸦传媒>ASCO: Myeloma Study Results Inconclusive

CHICAGO -- A trial comparing two immunomodulatory regimens for myeloma failed to demonstrate noninferiority for the newer drug.

<乌鸦传媒>ASCO: Combo Extends PFS in Relapsed Myeloma

CHICAGO -- Progression-free survival in relapsed/refractory myeloma increased significantly in patients treated with a three-drug regimen that included panobinostat versus a two-drug regimen, a randomized trial showed.

<乌鸦传媒>ASCO: Targeting PD-1 Works in Advanced Melanoma

CHICAGO -- Two studies indicate that using investigative immunotherapy drugs improves survival and response in patients with metastatic melanoma, researchers said here.

<乌鸦传媒>ASCO: Antibody Adds 6 Weeks to Squamous NSCLC Survival

CHICAGO -- The novel anti-EGFR monoclonal antibody necitumumab modestly improved survival in squamous non-small cell lung cancer (NSCLC) in a pivotal trial, but many called the effect too small to count.

<乌鸦传媒>ASCO: Targeted Combo Extends PFS in Ovarian Ca

CHICAGO -- Progression-free survival almost doubled in women with platinum-sensitive relapsed ovarian cancer treated with two targeted drugs instead of one, investigators reported here.

<乌鸦传媒>ASCO: Ipilimumab Cuts Relapse but Safety Issues Remain

CHICAGO -- High-risk melanoma patients have a reduced level of relapse if they are taking the monoclonal antibody ipilimumab (Yervoy) when compared with placebo, researchers said here.

<乌鸦传媒>Medtronic's Infuse Moves From Operating Room to Courtroom

An investigative series by 乌鸦传媒/Milwaukee Journal Sentinel has been tracking the spinal fusion device called Infuse in a 4-year-long series and now reports how a flawed FDA system for device approval may have led to a long string of adverse events culminating in thousands of liability suits.

<乌鸦传媒>FDA Warns of Cancer Risk With Laparoscopic Device

WASHINGTON -- Hysterectomy and procedures to remove uterine fibroids should avoid use of laparoscopic power morcellation, according to a safety advisory from the Food and Drug Administration.

<乌鸦传媒>Cologuard Cancer Test Aces FDA Panel Review

WASHINGTON -- An FDA advisory committee unanimously affirmed the safety and efficacy of a DNA stool test for colorectal cancer screening.

<乌鸦传媒>Anti-PARP Tx Works in Advanced Ovarian Cancer

TAMPA, Fla. -- Advanced ovarian cancer treated with PARP inhibitor maintenance therapy had significant improvement in progression-free survival, extending beyond first progression, investigators reported.

<乌鸦传媒>Cancer Ascites Responds to Outpatient Tx

TAMPA, Fla. -- Outpatient treatment of malignant ascites with a monoclonal antibody proved safe and feasible and led to a survival benefit in gynecologic cancer patients who could receive chemotherapy, a small clinical study showed.

<乌鸦传媒>OncoBriefs: Myeloma Tx, In Situ Melanoma

Superficial melanoma conferred a risk of recurrent invasive melanoma similar to that of primary invasive melanoma, Australian investigators reported. The study is one of several oncology-related news items summarized in OncoBriefs.

<乌鸦传媒>Tamoxifen Found in Bodybuilding Supplement

British researchers have found tamoxifen in supplements used by bodybuilders -- an active ingredient that isn't clearly labeled on the bottle.

<乌鸦传媒>Is There a Flaw in This Large Vitamin D Trial?

A co-principal investigator of the VITAL trial addresses the possibility that out-of-study testing of vitamin D levels and initiation of high-dose supplementation could be a limitation, but not a serious one.

<乌鸦传媒>Bodybuilders Bulk Up Using ... Cancer Drugs?

While steroids are all-stars among performance-enhancing drugs, breast cancer drugs are a lesser-known staple of doping regimens, as are some investigational agents that aren't available on any regulated market.

鈥�

70

鈥�